Elisabeth C. Moyal

Toulouse, FR 
Toulouse, FR 

Overview

Elisabeth Moyal practices practicing medicine in Toulouse, France.

Her clinical expertise encompasses Oligodendroglioma, Astrocytoma, Glioblastoma, and Glioma.

She is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Toulouse, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase III Randomized Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma : Standard 3D Conformational Radiotherapy Versus Intensity-modulated Radiotherapy With Simultaneous-integrated Boost Guided by Magnetic Resonance Spectroscopic Imaging
Phase III Randomized Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma : Standard 3D Conformational Radiotherapy Versus Intensity-modulated Radiotherapy With Simultaneous-integrated Boost Guided by Magnetic Resonance Spectroscopic Imaging
Enrollment Status: Terminated
Publish Date: April 14, 2026
Intervention Type: Radiation
Study Phase: Phase 3
Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study
Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study
Enrollment Status: Completed
Publish Date: April 14, 2026
Intervention Type: Procedure
Study Phase: Not Applicable
View 1 Less Clinical Trial

9 Total Publications

TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma.
TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma.
Journal: Neuro-oncology advances
Published: May 30, 2024

Frequently Asked Questions about Elisabeth C. Moyal

Is Elisabeth C. Moyal a top-rated expert for Oligodendroglioma?

MediFind is an objective health platform that identifies experts based on real-world data. Elisabeth C. Moyal is classified as an Experienced expert for Oligodendroglioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Elisabeth C. Moyal participate in research or clinical trials?

Yes. Elisabeth C. Moyal has published 9 articles and abstracts on conditions like Oligodendroglioma. You can view a list of Elisabeth C. Moyal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Moyal's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile